Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 20/20 | 0.65 |
| ▸ | KLKB1 | P03952 | 11/20 | 0.65 |
| ▸ | F10 | P00742 | 4/20 | 0.55 |
| ▸ | PLG | P00747 | 4/20 | 0.55 |
| ▸ | PLAT | P00750 | 3/20 | 0.55 |
| ▸ | PROC | P04070 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | F9 | P00740 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999660 | 1.00 | F11 (0.65) | F11KLKB1F10PLGPLAT | |
| SCHEMBL2999667 | 1.00 | F11 (0.65) | F11KLKB1F10PLGPLAT | |
| SCHEMBL3003803 | 0.94 | F11 (0.65) | F11KLKB1 | |
| SCHEMBL3003802 | 0.94 | F11 (0.65) | F11KLKB1 | |
| SCHEMBL3003806 | 0.94 | F11 (0.65) | F11KLKB1 | |
| SCHEMBL3008809 | 0.91 | F11 (0.75) | F11KLKB1F10PLGPLAT | |
| SCHEMBL3008813 | 0.91 | F11 (0.75) | F11KLKB1F10PLGPLAT | |
| SCHEMBL3008814 | 0.91 | F11 (0.75) | F11KLKB1F10PLGPLAT | |
| SCHEMBL3666777 | 0.90 | F11 (0.59) | F11KLKB1F10PLGPLAT | |
| SCHEMBL3666774 | 0.90 | F11 (0.59) | F11KLKB1F10PLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | F11 1/4885KLKB1 5/4885F10 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.